logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Janssen Biotech, Inc. drugs

    FiltersReset Filters
    16 results

    • akeega

      (NIRAPARIB TOSYLATE MONOHYDRATE and ABIRATERONE ACETATE)
      Janssen Biotech, Inc.
      Usage: AKEEGA, in combination with prednisone, is indicated for adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). Treatment selection should be based on an FDA-approved test for AKEEGA.

    • darzalex

      (Daratumumab)
      Janssen Biotech, Inc.
      Usage: DARZALEX is indicated for adult patients with multiple myeloma, used in various combinations with other therapies for newly diagnosed patients and those who are relapsed or refractory, including as monotherapy after multiple prior treatments.

    • darzalex faspro

      (daratumumab and hyaluronidase-fihj (human recombinant))
      Janssen Biotech, Inc.
      Usage: DARZALEX FASPRO is indicated for treating adult patients with multiple myeloma, either in combination with other therapies or as monotherapy after multiple prior treatments. It is also approved for newly diagnosed light chain amyloidosis in combination with specific medications, with ongoing approval contingent on further clinical trials.

    • imaavy - nipocalimab injection, solution, concentrate

      (Nipocalimab)
      Janssen Biotech, Inc.

    • infliximab - infliximab injection, powder, lyophilized, for solution

      (Infliximab)
      Janssen Biotech, Inc.

    • lazcluze

      (lazertinib)
      Janssen Biotech, Inc.
      Usage: LAZCLUZE, in combination with amivantamab, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations (exon 19 deletions or exon 21 L858R) as determined by an FDA-approved test.

    • remicade

      (INFLIXIMAB)
      Janssen Biotech, Inc.
      Usage: REMICADE is indicated for treating moderate to severe Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis in adults. It is also approved for pediatric Crohn's and ulcerative colitis. The drug helps induce and maintain remission and reduce symptoms.

    • rybrevant

      (Amivantamab)
      Janssen Biotech, Inc.
      Usage: RYBREVANT is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations, both as a first-line treatment and for those previously treated, in combination with approved therapies or as a single agent.

    • simponi

      (golimumab)
      Janssen Biotech, Inc.
      Usage: SIMPONI is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis (with methotrexate), active psoriatic arthritis (alone or with methotrexate), active ankylosing spondylitis, and moderately to severely active ulcerative colitis in patients with corticosteroid dependence or inadequate response to previous therapies.

    • simponi aria

      (golimumab)
      Janssen Biotech, Inc.
      Usage: SIMPONI ARIA is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults, active psoriatic arthritis in patients aged 2 and older, active ankylosing spondylitis in adults, and active polyarticular juvenile idiopathic arthritis in patients aged 2 and older.